Company · CIK 0001636050
Sio Gene Therapies Inc.
Exchange
—
Entity type
operating
Fiscal year end
Mar 31
Headquarters
Search this company’s filings
Search features10 guest searches · Free accounts get 10 a day · No credit card
On the record
Recent filings
- 8-KCurrent report0001636050-23-000016 · 208.4 KBSEC(opens sec.gov)
- 8-KCurrent report0001636050-23-000011 · 202.1 KBSEC(opens sec.gov)
- 8-KCurrent report0001636050-23-000008 · 370.1 KBSEC(opens sec.gov)
- 10-QQuarterly update0001636050-23-000007 · 3.3 MBSEC(opens sec.gov)
- SC 13G/ASio Gene Therapies Inc.0000919574-23-000939 · 107.1 KBSEC(opens sec.gov)
- SC 13GSio Gene Therapies Inc.0001104659-23-018477 · 75.5 KBSEC(opens sec.gov)
- 8-KCurrent report0001636050-22-000054 · 303.9 KBSEC(opens sec.gov)
- 8-KCurrent report0001636050-22-000051 · 373.1 KBSEC(opens sec.gov)
- 10-QQuarterly update0001636050-22-000050 · 3.4 MBSEC(opens sec.gov)
- 8-KCurrent report0001636050-22-000043 · 188.2 KBSEC(opens sec.gov)
Insiders
- Adasczik MichaelPrincipal Accounting Officer
- Altmeyer MarkPres (ASG) & Chief Comm. Ofc.
- Bazley Mathew C.General Counsel
- Bickerstaff GeorgeDirector
- Cheruvu PavanDirector, Chief Executive Officer
- Corcoran GavinChief R&D Officer
- Cvijic Christine MikailChief Admin Officer and GC
- Dexcel Pharma Technologies Ltd.See remarks
- Dexxon Holdings Ltd.See remarks
- FALBERG KATHRYN EDirector
Tickers
No tickers on record.
Addresses
business
1501 BROADWAY 12TH FLOOR
NEW YORK, NY, 10036
mailing
1501 BROADWAY 12TH FLOOR
NEW YORK, NY, 10036
Former names
- Axovant Gene Therapies Ltd.2020-11-13
- Axovant Sciences Ltd.2019-04-18
- Roivant Neurosciences Ltd.2015-03-24
Same industry